Another study showed that presence of co-mutated Trp53 reduces sensitivity to combined treatment with MEK inhibitor and chemotherapy in KrasG12C-driven murine lung cancer, which supports further clinical investigations of the combination therapy for patients with lung cancer harboring KRASG12C and wild-type p53 (17). This evidence concerns the gene TP53 and lung carcinoma.